NVAX Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Novavax, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.40 |
52 Week High | US$23.86 |
52 Week Low | US$3.53 |
Beta | 1.97 |
11 Month Change | 9.84% |
3 Month Change | 289.87% |
1 Year Change | 87.35% |
33 Year Change | -91.85% |
5 Year Change | 257.31% |
Change since IPO | -80.75% |
Recent News & Updates
Recent updates
Novavax: New Chapter, Questions Remain
Jun 20Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement
May 14Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 13Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely
May 07Novavax: Another Day Older And Deeper In
Mar 02Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry
Mar 02Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00
Mar 01Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems
Feb 23Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel
Sep 06Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook
Mar 05Shareholder Returns
NVAX | US Biotechs | US Market | |
---|---|---|---|
7D | -2.8% | -0.5% | -1.6% |
1Y | 87.3% | 14.9% | 19.8% |
Return vs Industry: NVAX exceeded the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: NVAX exceeded the US Market which returned 19.8% over the past year.
Price Volatility
NVAX volatility | |
---|---|
NVAX Average Weekly Movement | 34.1% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NVAX's share price has been volatile over the past 3 months.
Volatility Over Time: NVAX's weekly volatility has increased from 20% to 34% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 1,543 | John Jacobs | www.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
NVAX fundamental statistics | |
---|---|
Market cap | US$2.30b |
Earnings (TTM) | -US$398.71m |
Revenue (TTM) | US$996.61m |
2.2x
P/S Ratio-5.4x
P/E RatioIs NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NVAX income statement (TTM) | |
---|---|
Revenue | US$996.61m |
Cost of Revenue | US$947.57m |
Gross Profit | US$49.04m |
Other Expenses | US$447.75m |
Earnings | -US$398.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.84 |
Gross Margin | 4.92% |
Net Profit Margin | -40.01% |
Debt/Equity Ratio | -19.4% |
How did NVAX perform over the long term?
See historical performance and comparison